Le Nogue, Déborah
Lavaur, Jérémie
Milet, Aude
Ramirez-Gil, Juan Fernando
Katz, Ira
Lemaire, Marc
Farjot, Géraldine
Hirsch, Etienne C.
Michel, Patrick Pierre http://orcid.org/0000-0001-5607-3119
Funding for this research was provided by:
Agence Nationale de la Recherche (ANR-10-IAIHU-06, ANR-11-INBS-0011-NeurATRIS)
Air Liquide Santé International
Agence Nationale Recherche et Technologie (2014/0589)
Article History
Received: 6 October 2019
Accepted: 27 November 2019
First Online: 5 December 2019
Compliance with ethical standards
:
: AM, GF, IK, ML and J-FR are Air Liquide employees. Air Liquide has filed patent applications for the use of xenon as therapeutic agent for Parkinson’s disease and related disorders.